Cornelia Mutz
YOU?
Author Swipe
View article: Supplementary Table S3 from Combinatorial Drug Screening Identifies Ewing Sarcoma–specific Sensitivities
Supplementary Table S3 from Combinatorial Drug Screening Identifies Ewing Sarcoma–specific Sensitivities Open
Validation of PKC412 and BMS-754807 synergy in a panel of Ewing sarcoma cell lines. CI values are shown for each concentration point where the drugs were combined.
View article: Supplementary Table S2 from Combinatorial Drug Screening Identifies Ewing Sarcoma–specific Sensitivities
Supplementary Table S2 from Combinatorial Drug Screening Identifies Ewing Sarcoma–specific Sensitivities Open
Distribution of strong and very strong synergy across the three screens (appendix to Figure 1B and Figure 2A).
View article: Data from Combinatorial Drug Screening Identifies Ewing Sarcoma–specific Sensitivities
Data from Combinatorial Drug Screening Identifies Ewing Sarcoma–specific Sensitivities Open
Improvements in survival for Ewing sarcoma pediatric and adolescent patients have been modest over the past 20 years. Combinations of anticancer agents endure as an option to overcome resistance to single treatments caused by compensatory …
View article: Supplementary Table S2 from Combinatorial Drug Screening Identifies Ewing Sarcoma–specific Sensitivities
Supplementary Table S2 from Combinatorial Drug Screening Identifies Ewing Sarcoma–specific Sensitivities Open
Distribution of strong and very strong synergy across the three screens (appendix to Figure 1B and Figure 2A).
View article: Supplementary Table S1 from Combinatorial Drug Screening Identifies Ewing Sarcoma–specific Sensitivities
Supplementary Table S1 from Combinatorial Drug Screening Identifies Ewing Sarcoma–specific Sensitivities Open
Overview of compound libraries and sub-libraries used in the initial and parallel combinatorial screens.
View article: Supplementary Table S3 from Combinatorial Drug Screening Identifies Ewing Sarcoma–specific Sensitivities
Supplementary Table S3 from Combinatorial Drug Screening Identifies Ewing Sarcoma–specific Sensitivities Open
Validation of PKC412 and BMS-754807 synergy in a panel of Ewing sarcoma cell lines. CI values are shown for each concentration point where the drugs were combined.
View article: Supplementary Table S1 from Combinatorial Drug Screening Identifies Ewing Sarcoma–specific Sensitivities
Supplementary Table S1 from Combinatorial Drug Screening Identifies Ewing Sarcoma–specific Sensitivities Open
Overview of compound libraries and sub-libraries used in the initial and parallel combinatorial screens.
View article: Data from Combinatorial Drug Screening Identifies Ewing Sarcoma–specific Sensitivities
Data from Combinatorial Drug Screening Identifies Ewing Sarcoma–specific Sensitivities Open
Improvements in survival for Ewing sarcoma pediatric and adolescent patients have been modest over the past 20 years. Combinations of anticancer agents endure as an option to overcome resistance to single treatments caused by compensatory …
View article: Identifying the druggable interactome of EWS-FLI1 reveals MCL-1 dependent differential sensitivities of Ewing sarcoma cells to apoptosis inducers
Identifying the druggable interactome of EWS-FLI1 reveals MCL-1 dependent differential sensitivities of Ewing sarcoma cells to apoptosis inducers Open
Ewing sarcoma (EwS) is an aggressive pediatric bone cancer in need of more effective therapies than currently available. Most research into novel targeted therapeutic approaches is focused on the fusion oncogene EWSR1-FLI1, which is the ge…
View article: EWS-FLI1 confers exquisite sensitivity to NAMPT inhibition in Ewing sarcoma cells
EWS-FLI1 confers exquisite sensitivity to NAMPT inhibition in Ewing sarcoma cells Open
Ewing sarcoma (EwS) is the second most common bone cancer in children and adolescents with a high metastatic potential. EwS development is driven by a specific chromosomal translocation resulting in the generation of a chimeric EWS-ETS tra…
View article: The role of miR-17-92 in the miRegulatory landscape of Ewing sarcoma
The role of miR-17-92 in the miRegulatory landscape of Ewing sarcoma Open
MicroRNAs serve to fine-tune gene expression and play an important regulatory role in tissue specific gene networks. The identification and validation of miRNA target genes in a tissue still poses a significant problem since the presence o…
View article: Combinatorial Drug Screening Identifies Ewing Sarcoma–specific Sensitivities
Combinatorial Drug Screening Identifies Ewing Sarcoma–specific Sensitivities Open
Improvements in survival for Ewing sarcoma pediatric and adolescent patients have been modest over the past 20 years. Combinations of anticancer agents endure as an option to overcome resistance to single treatments caused by compensatory …
View article: EWS‐FLI1 impairs aryl hydrocarbon receptor activation by blocking tryptophan breakdown via the kynurenine pathway
EWS‐FLI1 impairs aryl hydrocarbon receptor activation by blocking tryptophan breakdown via the kynurenine pathway Open
Ewing sarcoma ( ES ) is an aggressive pediatric tumor driven by the fusion protein EWS ‐ FLI 1. We report that EWS ‐ FLI 1 suppresses TDO 2‐mediated tryptophan (TRP) breakdown in ES cells. Gene expression and metabolite analyses reveal an …